LundbeckH. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease - we call this Progress in Mind.

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. We have research centers in China, Denmark and the United States and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5 billion in 2014 (EUR 1.8 billion; USD 2.4 billion).

Lundbeck's shares are listed on the stock exchange in Copenhagen under the symbol "LUN". Lundbeck has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol "HLUYY".

Lundbeck RSS Channel

Display # 
Title Published Date
Kåre Schultz appointed new president and CEO of Lundbeck 06 May 2015
Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease 15 December 2013
The solid momentum continues - New Products up by 41% 06 November 2013
Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine) 01 October 2013
Vortioxetine, a new multimodal agent in development for the treatment of major depression 23 May 2013
Lundbeck is well on track to deliver on guidance for 2013 01 May 2013
Lundbeck announces positive results for Brintellix™ (vortioxetine) 08 April 2013
Lundbeck and Otsuka further expand their alliance and enter into collaboration 26 March 2013
Lundbeck on track to meet financial expectations and renew its product portfolio 08 August 2012
Lundbeck's Lu AE58054 meets primary endpoint 29 May 2012
Statistically significant clinical phase III results of Lu AA21004 14 May 2012
Lundbeck and Otsuka Pharmaceutical sign historic agreement 13 November 2011
Lundbeck's third quarter report 2011 - The positive momentum continues 10 November 2011
Lundbeck's first half report 2011 11 August 2011
Lundbeck's partner Mochida receives approval of Lexapro in Japan 23 April 2011
A new pharmaceutical candidate enters Lundbeck's development pipeline 30 March 2011
Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011 24 February 2011
The clinical phase III programme commenced on zicronapine 20 January 2011
First two clinical phase III studies confirm the profile of nalmefene 03 January 2011
Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis 16 December 2010

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]